Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -6.53
- Piotroski Score 2.00
- Grade Sector Weight
- Symbol (TBIO)
- Company Telesis Bio, Inc.
- Price $1.28
- Changes Percentage (15.04%)
- Change $0.17
- Day Low $1.06
- Day High $1.46
- Year High $15.46
Codex DNA, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. Its solutions include BioXp system that empowers researchers to go from a digital DNA sequence to endpoint-ready synthetic DNA; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice; BioXp kits that contain building blocks and reagents, including its Gibson Assembly branded reagents, for specific synthetic biology workflow applications; Cloud-based scripts; Benchtop reagents that contain all the reagents necessary to proceed with a specific synthetic biology workflow on the benchtop using products generated on the BioXp system; Biofoundry Services, which enable a customer to order and receive the BioXp system endpoint-ready products, such as genes, clones, cell-free amplified DNA, and variant libraries; and short oligo ligation assembly enzymatic DNA synthesis. It also serves government institutions, contract research organizations, and synthetic biology companies. The company was formerly known as SGI-DNA, Inc. and changed its name to Codex DNA, Inc. in March 2020. Codex DNA, Inc. was incorporated in 2011 and is headquartered in San Diego, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/10/2024
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$28.29
- Trailing P/E Ratio -0.13
- Forward P/E Ratio -0.13
- P/E Growth -0.13
- Net Income $-47,724,000
Income Statement
Quarterly
Annual
Latest News of TBIO
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
TBIO Stock Price | Telesis Bio Inc. Stock Quote (U.S.: Nasdaq) | MarketWatch
Telesis Bio, Inc. offers automated solutions for synthetic biology, including DNA and mRNA synthesis. Founded in 2011 by Daniel G. Gibson and J. Craig Venter, the company is based in San Diego, CA....
By MarketWatch | 2 months ago
